<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00825500</url>
  </required_header>
  <id_info>
    <org_study_id>AMDC-104-202</org_study_id>
    <secondary_id>24-October-2008</secondary_id>
    <nct_id>NCT00825500</nct_id>
  </id_info>
  <brief_title>Staccato Loxapine in Migraine (Out Patient)</brief_title>
  <official_title>A Multi-center, Randomized, Double-Blind, Placebo-Controlled, Single Dose Efficacy and Safety Study of StaccatoÂ® Loxapine for Inhalation in Outpatients With Migraine Headache</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexza Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexza Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assess the safety and efficacy of Staccato Loxapine in patients with moderate to severe
      migraine headache with or without aura in an outpatient setting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was designed to compare the safety and pharmacodynamic profiles of concomitant
      administration of single doses of ADASUVE and intramuscular (IM) lorazepam compared to that
      of each agent administered alone. Respiratory pharmacodynamics were monitored through
      recordings of respirations/minute and pulse oximetry. Other pharmacodynamic safety measures
      included effects on blood pressure, heart rate, sedation, and psychomotor measures of
      attention, information processing speed, reaction time, and coordination.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain-Relief at 2 Hours Post-treatment</measure>
    <time_frame>2 hours</time_frame>
    <description>Pain-Relief=pretreatment pain rating of 2 (moderate) or 3 (severe) and a rating of 0 (none) or 1 (mild) at the designated assessment time</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Photophobia Free</measure>
    <time_frame>2 hours</time_frame>
    <description>Free of Photophobia at 2 Hours Post-treatment</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">366</enrollment>
  <condition>Migraine Headache</condition>
  <arm_group>
    <arm_group_label>Inhaled Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inhaled Staccato Placebo (0 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inhaled Loxapine 1.25 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Inhaled Staccato Loxapine 1.25 mg, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inhaled Loxapine 2.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhaled Staccato Loxapine 2.5 mg, single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled Placebo</intervention_name>
    <description>Inhaled Staccato placebo (0 mg)</description>
    <arm_group_label>Inhaled Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled Loxapine 1.25 mg</intervention_name>
    <description>Inhaled Staccato Loxapine 1.25 mg, single dose</description>
    <arm_group_label>Inhaled Loxapine 1.25 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled Loxapine 2.5 mg</intervention_name>
    <description>Inhaled Staccato Loxapine 1.25 mg, single dose</description>
    <arm_group_label>Inhaled Loxapine 2.5 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Male or female between the ages of 18 to 65 years, inclusive

          -  History of migraine headache with or without aura (according to IHS Criteria 1.1 or
             1.2 for diagnosis beginning at least 6 months prior to study entry) (International
             Headache Society Clinical Trials Subcommittee, 2000)

          -  At least 3 migraine attacks in the last 3 month period (but not more than 8 migraine
             attacks in the last month)

          -  Pain rating of moderate or severe (on a none-mild- moderate-severe scale) prior to
             dosing

          -  Agreed not to use the study drug within 72 hours of a prior migraine attack

          -  Agreed not to use any acute migraine or pain medication within 48 hours prior to
             dosing (including over-the-counter [OTC] products); medications for migraine
             prophylaxis other than those that were exclusionary were permitted if stable doses had
             been given for at least 30 days prior to screening

          -  Agreed not to use medications (including OTC products) for motion sickness, tinnitus,
             or vertigo within 48 hours prior to dosing.

          -  Were able to speak, read, and understand English and were willing and able to provide
             written informed consent on an IRB-approved form prior to the initiation of any study
             procedures

          -  Were willing and able to comply with the study schedule and requirements, and agreed
             to return to the clinic within 5 working days of use of the study drug

          -  In good general health prior to study participation as determined by a detailed
             medical history, physical examination, 12-lead electrocardiogram (ECG), blood
             chemistry profile, hematology, urinalysis, and in the opinion of the investigator

          -  Female participants (if of child-bearing potential and sexually active) and male
             participants (if sexually active with a partner of child-bearing potential) who agreed
             to use a medically acceptable and effective birth control method throughout the study
             and for 1 week following the end of the study. Medically acceptable methods of
             contraception that could be used by the participant and/or his/her partner included
             abstinence, birth control pills or patches, diaphragm with spermicide, intrauterine
             device (IUD), condom with foam or spermicide, vaginal spermicidal suppository,
             surgical sterilization, and progestin implant or injection. Prohibited methods
             included the rhythm method, withdrawal, condoms alone, or diaphragm alone.

        Exclusion Criteria

          -  Use of antipsychotics (including butryophenones, phenothiazines, thioxanthenes,
             aripiprazle, olanzapine, risperidone), tricyclic antidepressants, trazodone,
             anticonvulsants (except topiramate), barbiturates, benzodiazepines, or lithium within
             14 days or 5 half-lives, whichever was longer, of randomization and at anytime
             throughout the study

          -  History of contraindications to anticholinergic agents (eg, bowel or urinary
             obstruction, stenosing peptic ulcers, narrow-angle glaucoma)

          -  History of allergy or intolerance to dibenzoxazepines (loxapine and amoxapine)

          -  History of extrapyramidal disorders, movement disorders including Parkinson's disease
             or neuroleptic malignant syndrome

          -  Female patients with a positive pregnancy test at screening or during randomization
             visit, or who were breastfeeding

          -  History within the past year of drug or alcohol dependence or abuse as defined by DSM
             IV

          -  History of syncope, unstable angina, myocardial infarction (within 6 months),
             congestive heart failure, or uncontrolled hypertension

          -  History of a major neurological disorder other than migraine (seizure disorder,
             subarachnoid bleeding, stroke, brain tumor, or transient ischemic attack)

          -  Any other disease(s), by history, physical examination, or laboratory abnormalities
             (including alanine aminotransferase [ALT] or aspartate aminotransferase [AST] &gt; 2-fold
             the upper limit of normal, total bilirubin &gt; 1.5 mg/dL, or creatinine &gt; 1.8 mg/dL),
             that in the investigator's opinion, would present undue risk to the patient or could
             confound the interpretation of study results

          -  History of asthma or chronic obstructive lung disease or any use of an inhaler
             prescribed for wheezing or bronchospasm in the past 5 years

          -  Receipt of an investigational drug within 30 days prior to the screening visit

          -  Considered by the investigator, for any reason, to be an unsuitable candidate for
             receiving loxapine, or unable to use the inhalation device
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roger K. Cady, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinvest</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter J. Bellafiore, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CNS Research, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arthur Elkind, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Elkind Headache Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roger K. Cady</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elkind Headache Center</name>
      <address>
        <city>Mount Vernon</city>
        <state>New York</state>
        <zip>10550</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CNS Research, Inc.</name>
      <address>
        <city>East Providence</city>
        <state>Rhode Island</state>
        <zip>02916</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2009</study_first_submitted>
  <study_first_submitted_qc>January 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2009</study_first_posted>
  <results_first_submitted>March 13, 2017</results_first_submitted>
  <results_first_submitted_qc>March 13, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 24, 2017</results_first_posted>
  <last_update_submitted>March 13, 2017</last_update_submitted>
  <last_update_submitted_qc>March 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Migraine headache</keyword>
  <keyword>Loxapine</keyword>
  <keyword>Staccato</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Loxapine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD submitted to regulatory authorities. Others may contact Alexza Pharmaceuticals, Inc. Please send your request to ClinicalTrialsInfo@alexza.com</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Inhaled Placebo</title>
          <description>Inhaled Staccato Placebo (0 mg)
Inhaled Placebo: Inhaled Staccato placebo (0 mg)</description>
        </group>
        <group group_id="P2">
          <title>Inhaled Loxapine 1.25 mg</title>
          <description>Inhaled Staccato Loxapine 1.25 mg, single dose
Inhaled Loxapine 1.25 mg: Inhaled Staccato Loxapine 1.25 mg, single dose</description>
        </group>
        <group group_id="P3">
          <title>Inhaled Loxapine 2.5 mg</title>
          <description>Inhaled Staccato Loxapine 2.5 mg, single dose
Inhaled Loxapine 2.5 mg: Inhaled Staccato Loxapine 1.25 mg, single dose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="125"/>
                <participants group_id="P2" count="121"/>
                <participants group_id="P3" count="120"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="125"/>
                <participants group_id="P2" count="121"/>
                <participants group_id="P3" count="120"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Population</population>
      <group_list>
        <group group_id="B1">
          <title>Inhaled Placebo</title>
          <description>Inhaled Staccato Placebo (0 mg)
Inhaled Placebo: Inhaled Staccato placebo (0 mg)</description>
        </group>
        <group group_id="B2">
          <title>Inhaled Loxapine 1.25 mg</title>
          <description>Inhaled Staccato Loxapine 1.25 mg, single dose
Inhaled Loxapine 1.25 mg: Inhaled Staccato Loxapine 1.25 mg, single dose</description>
        </group>
        <group group_id="B3">
          <title>Inhaled Loxapine 2.5 mg</title>
          <description>Inhaled Staccato Loxapine 2.5 mg, single dose
Inhaled Loxapine 2.5 mg: Inhaled Staccato Loxapine 1.25 mg, single dose</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="125"/>
            <count group_id="B2" value="121"/>
            <count group_id="B3" value="120"/>
            <count group_id="B4" value="366"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="125"/>
                    <measurement group_id="B2" value="121"/>
                    <measurement group_id="B3" value="120"/>
                    <measurement group_id="B4" value="366"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.5" spread="12.14"/>
                    <measurement group_id="B2" value="41.2" spread="12.19"/>
                    <measurement group_id="B3" value="42" spread="12.74"/>
                    <measurement group_id="B4" value="41.5" spread="12.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="229"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="79"/>
                    <measurement group_id="B4" value="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="125"/>
                    <measurement group_id="B2" value="121"/>
                    <measurement group_id="B3" value="120"/>
                    <measurement group_id="B4" value="366"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain-Relief at 2 Hours Post-treatment</title>
        <description>Pain-Relief=pretreatment pain rating of 2 (moderate) or 3 (severe) and a rating of 0 (none) or 1 (mild) at the designated assessment time</description>
        <time_frame>2 hours</time_frame>
        <population>ITT with LOCF Population</population>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Placebo</title>
            <description>Inhaled Staccato Placebo (0 mg)
Inhaled Placebo: Inhaled Staccato placebo (0 mg)</description>
          </group>
          <group group_id="O2">
            <title>Inhaled Loxapine 1.25 mg</title>
            <description>Inhaled Staccato Loxapine 1.25 mg, single dose
Inhaled Loxapine 1.25 mg: Inhaled Staccato Loxapine 1.25 mg, single dose</description>
          </group>
          <group group_id="O3">
            <title>Inhaled Loxapine 2.5 mg</title>
            <description>Inhaled Staccato Loxapine 2.5 mg, single dose
Inhaled Loxapine 2.5 mg: Inhaled Staccato Loxapine 1.25 mg, single dose</description>
          </group>
        </group_list>
        <measure>
          <title>Pain-Relief at 2 Hours Post-treatment</title>
          <description>Pain-Relief=pretreatment pain rating of 2 (moderate) or 3 (severe) and a rating of 0 (none) or 1 (mild) at the designated assessment time</description>
          <population>ITT with LOCF Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="121"/>
                <count group_id="O3" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="65"/>
                    <measurement group_id="O3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Photophobia Free</title>
        <description>Free of Photophobia at 2 Hours Post-treatment</description>
        <time_frame>2 hours</time_frame>
        <population>ITT with LOCF Population</population>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Placebo</title>
            <description>Inhaled Staccato Placebo (0 mg)
Inhaled Placebo: Inhaled Staccato placebo (0 mg)</description>
          </group>
          <group group_id="O2">
            <title>Inhaled Loxapine 1.25 mg</title>
            <description>Inhaled Staccato Loxapine 1.25 mg, single dose
Inhaled Loxapine 1.25 mg: Inhaled Staccato Loxapine 1.25 mg, single dose</description>
          </group>
          <group group_id="O3">
            <title>Inhaled Loxapine 2.5 mg</title>
            <description>Inhaled Staccato Loxapine 2.5 mg, single dose
Inhaled Loxapine 2.5 mg: Inhaled Staccato Loxapine 1.25 mg, single dose</description>
          </group>
        </group_list>
        <measure>
          <title>Photophobia Free</title>
          <description>Free of Photophobia at 2 Hours Post-treatment</description>
          <population>ITT with LOCF Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="121"/>
                <count group_id="O3" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AEs) were considered treatment related from the first exposure to study treatment until 30 days after the last treatment</time_frame>
      <desc>Subjects were instructed to carry out self-assessment for adverse events from dosing through 24 hours and recored in the patient diary</desc>
      <group_list>
        <group group_id="E1">
          <title>Inhaled Placebo</title>
          <description>Inhaled Staccato Placebo (0 mg)
Inhaled Placebo: Inhaled Staccato placebo (0 mg)</description>
        </group>
        <group group_id="E2">
          <title>Inhaled Loxapine 1.25 mg</title>
          <description>Inhaled Staccato Loxapine 1.25 mg, single dose
Inhaled Loxapine 1.25 mg: Inhaled Staccato Loxapine 1.25 mg, single dose</description>
        </group>
        <group group_id="E3">
          <title>Inhaled Loxapine 2.5 mg</title>
          <description>Inhaled Staccato Loxapine 2.5 mg, single dose
Inhaled Loxapine 2.5 mg: Inhaled Staccato Loxapine 1.25 mg, single dose</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="121"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="125"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="121"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="125"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="121"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="125"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="121"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Scientific Officer</name_or_title>
      <organization>Alexza Pharmaceuticals, Inc</organization>
      <phone>650.944.7777</phone>
      <email>jcassella@alexza.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

